Eris Lifesciences Presents Corporate Update and Acquisition Strategy

Eris Lifesciences Ltd has released a corporate presentation detailing its business segments, including Domestic Branded Formulations and International Business. The company highlights its strong market position in Anti-Diabetes therapy and Insulins, with a 6% and 16% market share respectively. It also notes a strong start for its Gx Semaglutide brand, Sundae. The presentation outlines significant investments and leveraged acquisitions totaling over ₹4,300 crore between FY23-FY26, aimed at entering high-value therapies and expanding its business, including recent entries into the Derma segment and acquisitions of injectable and other businesses. The company also emphasizes its R&D capabilities and state-of-the-art manufacturing facilities.